Investigating PP2A-based therapeutic strategies for KMT2A-rearranged acute leukemia [Video]

KMT2A-rearranged acute myeloid leukemia (AML) is an aggressive and chemoresistant disease subtype that confers a poor prognosis. In this interview, Maria Teresa Esposito, PhD, University of Surrey, Guildford, UK, provides an insight into the investigation of PP2A-based therapeutic strategies for KMT2A-rearranged leukemia, detailing the disease biology and discussing the potential for pharmacological interventions to target the SET-PP2A complex. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.